LENZ Therapeutics (LENZ) Long-Term Investments (2022)
LENZ Therapeutics (LENZ) posted quarterly Long-Term Investments of $15.3 million for Q4 2022, up 14.32% quarter-over-quarter from $13.4 million in Q3 2022.
LENZ Therapeutics (LENZ) Long-Term Investments (2022) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Long-Term Investments for 1 consecutive years, with $15.3 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Long-Term Investments changed N/A year-over-year to $15.3 million; the TTM figure through Dec 2022 stood at $15.3 million (changed N/A YoY), while the FY2022 annual figure was $15.3 million, changed N/A from the prior year.
- Long-Term Investments grew to $15.3 million in Q4 2022 per LENZ's latest filing, from $13.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $15.3 million in Q4 2022 and bottomed at $6.0 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 15.32 Mn |
| Sep 30, 2022 | 13.40 Mn |
| Jun 30, 2022 | 5.99 Mn |
| Mar 31, 2022 | 12.93 Mn |